Abacavir therapy for HIV treatment is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong association with the HLA-B*5701 allele. HLA-B*5701 typing can be used for genetic risk stratification prior to initiation of abacavir therapy.